Vivo Ventures is a life-sciences focused venture capital firm formed in 1996 with over $650M under management. Vivo Ventures is currently making investments from its $275M sixth fund into promising biotechnology and life science companies.

With over 90 years of scientific and operational expertise in biotechnology, Vivo makes investment decisions for the Funds and helps its portfolio companies develop corporate strategy, arrange licensing agreements and strategic alliances, recruit key management personnel, and acquire new products and technology to accelerate growth. Its current portfolio includes more than 60 private and public biotechnology companies in the areas of biopharmaceuticals, specialty pharmaceuticals, and medical devices.




Recent News

Lee's Pharmaceutical Signed a Subscription Agreement with Vivo Ventures Fund
Shatin, Hong Kong - August 12, 2009

AVANIR Announces Positive Phase III Study Results for Zenvia
Aliso Viejo, CA - August 11, 2009

Eiger BioPharmaceuticals Announces Initiation of CLEAN-1 HCV Phase 1b Trial
Palo Alto, CA - August 10, 2009

KangHui Medical Raises Series B-1 Extension Round
Palo Alto, CA - April 24, 2009

APT Pharmaceuticals Secures $32 Million in Series B Financing
Burlingame, CA - September 30, 2008

Sagent Completes $30 Million Series A Financing Extension
Schaumburg, IL - September 4, 2008